ArticleActa ophthalmologica2026
Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy.
Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for the development of subretinal fluid in the fellow eyes of patients with chronic central serous chorioretinopathy.Acta ophthalmologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo assess the risk of subretinal fluid (SRF) development in the fellow eye of chronic central serous chorioretinopathy (cCSC) patients with unilateral SRF at baseline.
methodsMedical records of 334 presumed cCSC patients were retrospectively reviewed. Multimodal imaging was evaluated, and the available optical coherence tomography (OCT) scans were screened for SRF development in the fellow eye during follow-up.
resultsOf 213 confirmed cCSC cases, 74 (35%) had bilateral SRF at baseline. Among 102 patients with unilateral SRF that met all inclusion criteria, 7/102 (7%) developed SRF in the fellow eye over a mean follow-up of 20.4 months. Retinal pigment epithelial (RPE) alterations in the fellow eye were present at baseline in 7/7 (100%) who developed SRF, compared to 59/95 (62%) in those who did not (p = 0.042). Subfoveal choroidal thickness (SFCT) was higher in the SRF-developing group (482.3 vs. 365.9 μm; p = 0.306), although not significantly. Hyperautofluorescence on fundus autofluorescence (FAF) at baseline occurred in 6/7 (86%) of the SRF-developing group versus 25/91 (28%) who did not (p = 0.004). The ellipsoid zone was interrupted in 5/7 (71%) of SRF-developing patients versus 28/95 (30%) who did not develop SRF (p = 0.005).
conclusionThe risk of SRF development in the fellow eye of cCSC patients with unilateral SRF is relatively low over a follow-up period of almost 2 years. No statistically significant risk factors were identified after correction for multiple testing; however, certain trends were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.